The turnover from transactions with Bulgarian shares reached just under BGN 6 million, and two-thirds of it (just over BGN 4 million) was formed by transactions with shares of Tchaikapharma High Quality Medicines. Another 4 companies formed another quarter of the turnover, SOFIX recorded a minimal decrease. Read the full article here in Bulgarian.
The Company reports about growth in sales of antibiotics and respiratory drugs Tchaikapharma High Quality Medicines Inc. reports revenue growth and profit more than doubling by the end of 2021. The company’s net profit at the end of the last quarter for 2021 amounted to BGN 1,667 million compared to BGN 604 thousand at […]
SOFIX was one of the most successful stock indices in 2021. The indicator outlined a successful trading on the Bulgarian Stock Exchange for both investors and public companies. For the twelve months of last year, the “blue chip” index grew by 42.23% to 635.68 points, showed a study by the newspaper. “Banker”. The main index […]
We say goodbye to a historic year, marked by unprecedented difficulties in medical, economical, political and of course, in pure human terms. With hard work and effective oganization, in this difficult time, we could assure that the Bulgarian population had access to reliable and affordable medical prevention and early COVID-19 treatment with hydroxychloroquine. At the […]
Tchaikapharma High Quality Medicines Inc. remains the most expensive Bulgarian company on the Bulgarian Stock Exchange. After the market capitalization of the pharmaceutical company exceeded BGN 1 billion at the end of June, in July, August and September it added more value to its stock market valuation. The full article is available here in Bulgarian.